Vietnam's pharmaceutical industry is experiencing robust growth, with exports totaling $312 million last year, positioning the country as the fourth-largest exporter in Southeast Asia. This achievement underscores the sector's strategic importance in the regional B2B landscape, particularly for contract manufacturing and supply chain partners. According to the Drug Administration of Vietnam (DAV) under the Ministry of Health (MoH), the market has maintained a stable annual growth rate of 6 to 8 percent. Projections indicate the total market value will expand from approximately $2.7 billion in 2015 to around $8 billion by 2026, making Vietnam one of Asia's fastest-growing pharmaceutical markets.

Currently, 245 enterprises are involved in importing and exporting medicines, pharmaceutical materials, and related services across the nation. Among these, 67 companies focus on pharmaceutical and ingredient exports. Foreign-invested enterprises dominate, contributing about 75 percent or $230 million to the export value, while domestic firms account for $82 million. Primary export destinations include Asia, Europe, and Japan, highlighting Vietnam's integration into global pharmaceutical supply chains. This export performance is bolstered by continuous enhancements in domestic production capabilities, with 243 factories now compliant with GMP-WHO standards—up significantly from 158 in 2015. Notably, 29 facilities meet higher benchmarks such as GMP-EU and PIC/S-GMP, enabling competitive participation in international contract manufacturing (CMO) and contract research organization (CRO) activities.

Domestic production satisfies about 60 percent of drug quantity demands and 46 percent of value needs, reflecting advancements in self-sufficiency critical for pharmaceutical executives managing supply chain risks. Vietnamese enterprises have mastered production of all 13 WHO essential drug groups, supply 11 of 12 vaccines for the Expanded Programme on Immunisation, and are progressing in biological materials, raw materials, and excipients. These capabilities position Vietnam as a reliable partner for multinational pharmaceutical companies seeking diversified manufacturing bases in Asia, especially amid geopolitical tensions affecting other regional hubs.

Regulatory advancements are accelerating industry efficiency. The MoH reduced administrative procedures in pharmaceuticals and cosmetics from 124 to 75 last year—a 40 percent cut—lowering compliance costs for businesses. Digital transformation is a priority, with 47 online public services available, 37 fully processed, and 24 integrated into the National Public Service Portal. This enhances transparency and streamlines document processing for procurement professionals and regulatory teams. In 2025, over 40,000 documents for drug imports, exports, and registrations were handled, with nearly 95 percent of new drug applications processed on time, averaging 114.5 days.

Strategic infrastructure developments further solidify Vietnam's B2B appeal. The MoH is establishing two specialized industrial zones: a 300-hectare pharmaceutical and biotechnology park in Hưng Yên Province, set to break ground in Q2 2026, and another in Ho Chi Minh City advancing through procedures. These zones will focus on high-value contract manufacturing, R&D outsourcing, and biotechnology, attracting CRO/CMO leaders and technology vendors. Looking to 2026, priorities include completing legal frameworks, linking administrative reforms with decentralization, advancing digital tools, and pursuing self-sufficiency in drug supply, particularly for rare medicines.

For pharmaceutical executives, these developments signal opportunities in Vietnam's evolving ecosystem. The combination of export growth, GMP upgrades, regulatory streamlining, and new industrial parks reduces risks in Asian supply chains. Companies like those in contract packaging, pharmaceutical process machinery, and quality assurance can leverage Vietnam's cost-effective, compliant facilities. Moreover, the emphasis on digital compliance aids validation and legislation efforts, while export-oriented production supports pharmaceutical distribution and logistics. As Vietnam ranks fourth in SEA exports, it emerges as a key alternative for firms diversifying from higher-cost or geopolitically vulnerable locations, ensuring resilient B2B operations in the pharmaceutical tech sector.

The DAV's efforts in information technology application have finalized 100 percent of planned legal documents, fostering a predictable environment for investments in laboratory instrumentation, cleanroom solutions, and pharmaceutical manufacturing equipment. This holistic approach not only meets domestic needs but positions Vietnam for expanded roles in global partnerships, contract services, and economic development within Asia's pharmaceutical landscape.